Loading…

Synthesis and Structure−Activity Relationships of β- and α-Piperidine Sulfone Hydroxamic Acid Matrix Metalloproteinase Inhibitors with Oral Antitumor Efficacy

α-Piperidine-β-sulfone hydroxamate derivatives were explored that are potent for matrix metalloproteinases (MMP)-2, -9, and -13 and are sparing of MMP-1. The investigation of the β-sulfones subsequently led to the discovery of hitherto unknown α-sulfone hydroxamates that are superior to the correspo...

Full description

Saved in:
Bibliographic Details
Published in:Journal of medicinal chemistry 2005-10, Vol.48 (21), p.6713-6730
Main Authors: Becker, Daniel P, Villamil, Clara I, Barta, Thomas E, Bedell, Louis J, Boehm, Terri L, DeCrescenzo, Gary A, Freskos, John N, Getman, Daniel P, Hockerman, Susan, Heintz, Robert, Howard, Susan Carol, Li, Madeleine H, McDonald, Joseph J, Carron, Chris P, Funckes-Shippy, Chris L, Mehta, Pramod P, Munie, Grace E, Swearingen, Craig A
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:α-Piperidine-β-sulfone hydroxamate derivatives were explored that are potent for matrix metalloproteinases (MMP)-2, -9, and -13 and are sparing of MMP-1. The investigation of the β-sulfones subsequently led to the discovery of hitherto unknown α-sulfone hydroxamates that are superior to the corresponding β-sulfones in potency for target MMPs, selectivity vs MMP-1, and exposure when dosed orally. α-Piperidine-α-sulfone hydroxamate 35f (SC-276) was advanced through antitumor and antiangiogenesis assays and was selected for development. Compound 35f demonstrates excellent antitumor activity vs MX-1 breast tumor in mice when dosed orally as monotherapy or in combination with paclitaxel.
ISSN:0022-2623
1520-4804
DOI:10.1021/jm0500875